Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of DMOT4039A in unresectable pancreatic or platinum-resistant ovarian cancer
NL-OMON35699Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Apr 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DMOT4039A in pancreatic cancer (PC) and ovarian cancer (4 arms), sponsored by Genentech. Primary endpoints: Incidence and nature of dose-limiting toxicities, Area under the concentration-time curve and 8 more. Started Apr 2012; status: active, not recruiting.
02
Drugs
DMOT4039A
03
Conditions
pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NL-OMON35699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35699.